ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1892

Genicular Nerve Block for Pain Management in Patients with Knee Osteoarthritis: A Randomised Double-blind Placebo Controlled Trial

Ernst Shanahan1, Fin Cai2, Frank Voyvodic2, Suellen Lyne2, Richard Woodman1, Kokum Dissanayake2, Kate Paddick2, Giovanna Cheung2 and Lucinda Robinson2, 1Flinders University, Adelaide, Australia, 2SALHN, Adelaide, Australia

Meeting: ACR Convergence 2022

Keywords: Osteoarthritis, pain, Randomized Trial

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 14, 2022

Title: Osteoarthritis – Clinical Poster

Session Type: Poster Session D

Session Time: 1:00PM-3:00PM

Background/Purpose: To determine whether Genicular Nerve Block (GNB) is an efficacious treatment for patients with knee osteoarthritis (OA)

Methods: Adults with symptomatic knee OA for greater than 3 months were invited to participate. Patients were randomised into two groups. Under ultrasound guidance subjects in the treatment arm received 5.7 mg (1 ml) of celestone and 3 mls of 0.5% of bupivacaine infiltrated around three genicular nerves, with subjects in the placebo receiving three 1 ml normal saline injections. Participants were followed up for 3 months with primary outcome measures being pain, stiffness and disability measured on the Western Ontario and McMaster Universities Arthritis index (WOMAC) score, and pain measured by a 100-point Visual Analogue Scale (VAS) measured at baseline,2, 4, 8 and 12 weeks. Secondary outcome measures included patient satisfaction measured using the Global Perceived Effect (GPES) score and the Intermittent and Constant Osteoarthritis Pain Score (knee version).

Results: All mean scores showed clinical and statistical improvement in the treatment arm at all time points compared to baseline. Of the primary outcome measures, the WOMAC score improved from a baseline of 55 (CI 49-61) to 33 (CI 27-39) at week 2, 34 (CI 28-40) at week 4, 39 (CI 33-45) at week 8 and 43 (CI 36-49) at week 12. The placebo group showed a small (non-significant) placebo effect at each time interval. VAS scores showed similar improvements as did the secondary outcome measures. All scores differed between the two groups at each time point, with improvement across all weeks in the treatment arm compared with baseline and the placebo group. There were no reported adverse outcomes.

Conclusion: These results demonstrate that GNB is an efficacious treatment for knee pain from OA and is a useful alternative for the management of this condition.

Supporting image 1

Total WOMAC scores

Supporting image 2

VAS scores


Disclosures: E. Shanahan, None; F. Cai, None; F. Voyvodic, None; S. Lyne, None; R. Woodman, None; K. Dissanayake, None; K. Paddick, None; G. Cheung, None; L. Robinson, None.

To cite this abstract in AMA style:

Shanahan E, Cai F, Voyvodic F, Lyne S, Woodman R, Dissanayake K, Paddick K, Cheung G, Robinson L. Genicular Nerve Block for Pain Management in Patients with Knee Osteoarthritis: A Randomised Double-blind Placebo Controlled Trial [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/genicular-nerve-block-for-pain-management-in-patients-with-knee-osteoarthritis-a-randomised-double-blind-placebo-controlled-trial/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/genicular-nerve-block-for-pain-management-in-patients-with-knee-osteoarthritis-a-randomised-double-blind-placebo-controlled-trial/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology